Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1

NCT06462404 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT06462404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2024
Completion date
March 17, 2025
Enrollment
22 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy type 1 (nt1)